Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial-Reference-Cited by-同舟云学术

Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial

Published:2020-07-09 Issue:9 Volume:43 Page:e108-e110
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Crowley Matthew J.¹²^ORCID,McGuire Darren K.³^ORCID,Alexopoulos Anastasia-Stefania¹²,Jensen Thomas Jon⁴,Rasmussen Søren⁴,Saevereid Hans A.⁴,Verma Subodh⁵^ORCID,Buse John B.⁶

Affiliation:

1. Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University School of Medicine, Durham, NC

2. Durham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham, NC

3. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

4. Novo Nordisk A/S, Søborg, Denmark

5. Division of Cardiac Surgery, St. Michael’s Hospital and University of Toronto, Toronto, Ontario, Canada

6. Division of Endocrinology and Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC

Funder

Health Services Research and Development

National Institute of Diabetes and Digestive and Kidney Diseases

National Center for Advancing Translational Sciences

Novo Nordisk

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/43/9/e108/630935/dc200437.pdf

Reference8 articles.

1. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Davies;Diabetes Care,2018

2. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD;Cosentino;Eur Heart J,2020

3. Liraglutide and cardiovascular outcomes in type 2 diabetes;Marso;N Engl J Med,2016

4. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments;Austin;Stat Med,2014

5. The performance of different propensity score methods for estimating marginal hazard ratios;Austin;Stat Med,2013

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ¿Ha cambiado el primer tratamiento de la diabetes mellitus tipo 2?;Medicina Clínica;2024-07

2. Trends in antidiabetes medication use among hospitalised patients with type 2 diabetes: a retrospective single-centre cohort study;BMJ Open;2024-06

3. Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes;Journal of Diabetes & Metabolic Disorders;2024-03-25

4. Advances in the management of type 2 diabetes in adults;BMJ Medicine;2023-09

5. Update on Medical Management of Diabetes;Orthopedic Clinics of North America;2023-07